Kezar Life Sciences (NASDAQ:KZR) Earns “Buy” Rating from Cowen

Cowen reissued their buy rating on shares of Kezar Life Sciences (NASDAQ:KZR) in a research note issued to investors on Thursday morning, AnalystRatings.com reports.

A number of other analysts have also weighed in on KZR. Zacks Investment Research lowered shares of Kezar Life Sciences from a hold rating to a sell rating in a research report on Wednesday, July 10th. ValuEngine raised shares of Kezar Life Sciences from a hold rating to a buy rating in a research report on Thursday, August 1st. Finally, HC Wainwright assumed coverage on shares of Kezar Life Sciences in a research report on Monday, July 29th. They issued a buy rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $17.50.

Shares of NASDAQ KZR traded up $0.21 during mid-day trading on Thursday, hitting $4.88. 67,979 shares of the company’s stock traded hands, compared to its average volume of 54,024. The business has a 50-day moving average of $6.46. The company has a debt-to-equity ratio of 0.06, a current ratio of 20.32 and a quick ratio of 21.81. The company has a market capitalization of $89.37 million, a P/E ratio of -2.16 and a beta of 0.61. Kezar Life Sciences has a 1 year low of $4.12 and a 1 year high of $36.33.

Kezar Life Sciences (NASDAQ:KZR) last announced its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.02. On average, equities analysts expect that Kezar Life Sciences will post -2.01 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. FMR LLC raised its position in Kezar Life Sciences by 12.6% in the 4th quarter. FMR LLC now owns 2,849,233 shares of the company’s stock worth $67,242,000 after purchasing an additional 318,852 shares during the period. BlackRock Inc. raised its position in Kezar Life Sciences by 1.9% in the 4th quarter. BlackRock Inc. now owns 245,932 shares of the company’s stock worth $5,804,000 after purchasing an additional 4,486 shares during the period. Geode Capital Management LLC grew its stake in Kezar Life Sciences by 126.7% in the 4th quarter. Geode Capital Management LLC now owns 58,046 shares of the company’s stock worth $1,369,000 after acquiring an additional 32,441 shares in the last quarter. Northern Trust Corp grew its stake in Kezar Life Sciences by 8.7% in the 4th quarter. Northern Trust Corp now owns 56,993 shares of the company’s stock worth $1,345,000 after acquiring an additional 4,581 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Kezar Life Sciences in the 1st quarter worth about $704,000. 51.89% of the stock is currently owned by institutional investors.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis.

See Also: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.